MarketCap
Facebook
X
TelegramAnnual report 2025
added 05-26-2026
OpGen Net Income 2011-2026 | OPGN
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income OpGen
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 23.6 M | 12 M | -32.7 M | -37.3 M | -34.8 M | -26.2 M | -12.4 M | -13.4 M | -15.4 M | -19.2 M | -17.4 M | -5.67 M | -10.1 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 23.6 M | -37.3 M | -14.5 M |
Quarterly Net Income OpGen
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -609 K | 3.51 M | -408 K | - | 8.93 M | -1.58 M | 288 K | - | -4.06 M | -5.83 M | -5.74 M | - | -14.1 M | -5.84 M | -6.8 M | - | -6.06 M | -7.09 M | -14.9 M | - | -7.68 M | -7.48 M | -3.95 M | - | -3.48 M | -2.59 M | -3.85 M | - | -3.26 M | -3.33 M | -3.05 M | - | -3.27 M | -4.21 M | -4.98 M | - | -4.85 M | -5.05 M | -4.51 M | - | -4.67 M | -5.36 M | -2.6 M | - | -1.61 M | -1.46 M | -1.2 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 8.93 M | -14.9 M | -3.96 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Diagnostics research industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
-26.1 M | - | -8.98 % | $ 14.8 K |  USA |
 |
Centogene N.V.
CNTG
|
-46.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Heska Corporation
HSKA
|
-19.9 M | - | - | $ 1.31 B | USA |
 |
Celcuity
CELC
|
-177 M | $ 88.28 | -4.53 % | $ 4.13 B | USA |
|
Akumin
AKU
|
-157 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Co-Diagnostics
CODX
|
-46.9 M | $ 5.63 | -2.26 % | $ 7.49 M | USA |
 |
Castle Biosciences
CSTL
|
-24.2 M | $ 21.01 | -2.73 % | $ 609 M | USA |
 |
Fulgent Genetics
FLGT
|
-60.5 M | $ 19.15 | -1.79 % | $ 589 M | USA |
 |
Aspira Women's Health
AWH
|
-12.8 K | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-50 M | - | -61.36 % | $ 2.46 M | USA |
 |
Guardant Health
GH
|
-416 M | $ 125.61 | -5.6 % | $ 15.7 B | USA |
 |
Biocept
BIOC
|
-32.1 M | - | -13.05 % | $ 7.29 M | USA |
 |
Interpace Biosciences
IDXG
|
24.6 M | $ 1.67 | -6.7 % | $ 7.39 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-1.81 M | - | - | $ 562 M |  Britain |
 |
Illumina
ILMN
|
850 M | $ 162.32 | -3.42 % | $ 25.2 B | USA |
 |
CareDx, Inc
CDNA
|
-21.4 M | $ 22.25 | -3.76 % | $ 1.19 B | USA |
 |
Chembio Diagnostics
CEMI
|
-23.3 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
4.14 M | - | - | $ 9.42 M |  Israel |
 |
ICON Public Limited Company
ICLR
|
229 M | $ 149.45 | -2.19 % | $ 11.7 B |  Irlanda |
 |
HTG Molecular Diagnostics
HTGM
|
-21.6 M | - | -20.0 % | $ 1.06 M | USA |
 |
Lantheus Holdings
LNTH
|
234 M | $ 100.98 | -1.79 % | $ 6.82 B | USA |
 |
Global Cord Blood Corporation
CO
|
501 M | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
-53 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-12 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-811 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
-101 M | - | -11.32 % | $ 2.94 M | USA |
 |
NeoGenomics
NEO
|
-108 M | $ 10.9 | -3.63 % | $ 1.4 B | USA |
 |
Natera
NTRA
|
-208 M | $ 215.31 | -3.06 % | $ 29.4 B | USA |
 |
Charles River Laboratories International
CRL
|
-144 M | $ 181.34 | -2.4 % | $ 8.99 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
197 M | - | - | $ 10.7 B | USA |
 |
Pacific Biosciences of California
PACB
|
-546 M | $ 1.45 | -11.04 % | $ 435 M | USA |
 |
Medpace Holdings
MEDP
|
451 M | $ 454.25 | -0.97 % | $ 13.1 B | USA |
 |
Mettler-Toledo International
MTD
|
869 M | $ 1 154.33 | -2.22 % | $ 23.8 B |  Schweiz |
 |
Exact Sciences Corporation
EXAS
|
-208 M | - | - | $ 19.8 B | USA |
 |
Myriad Genetics
MYGN
|
-366 M | $ 4.57 | -2.56 % | $ 423 M | USA |
 |
National Research Corporation
NRC
|
11.6 M | $ 19.14 | -3.09 % | $ 428 M | USA |
 |
Personalis
PSNL
|
-81.3 M | $ 10.75 | -11.16 % | $ 959 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
897 M | $ 26.11 | 0.46 % | $ 24.8 B |  Niderland |
 |
Senseonics Holdings
SENS
|
-69.1 M | $ 6.67 | -4.85 % | $ 278 M | USA |
 |
QIAGEN N.V.
QGEN
|
425 M | - | - | $ 10.6 B | Niderland |
 |
Soleno Therapeutics
SLNO
|
20.9 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
-4.97 M | $ 2.12 | -1.17 % | $ 4.87 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
876 M | $ 265.15 | 1.6 % | $ 22.1 B | USA |
 |
Twist Bioscience Corporation
TWST
|
-77.7 M | $ 69.22 | -6.37 % | $ 4.14 B | USA |
 |
Thermo Fisher Scientific
TMO
|
6.7 B | $ 472.8 | -1.91 % | $ 178 B | USA |
 |
Trinity Biotech plc
TRIB
|
-31.2 M | $ 0.67 | -2.43 % | $ 241 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
-12.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Waters Corporation
WAT
|
643 M | $ 365.36 | -2.95 % | $ 21.8 B | USA |
 |
Neogen Corporation
NEOG
|
-1.09 B | $ 8.9 | -2.41 % | $ 1.93 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
992 M | $ 200.29 | 2.13 % | $ 22.2 B | USA |